Brief: Jazz Pharmaceuticals Q2 Adjusted EPS USD 5.71 Vs. IBES Estimate USD 6.18
03/08/2026 21:06
BRIEF-Jazz Pharmaceuticals Q2 Adjusted EPS USD 5.71 Vs. IBES Estimate USD 6.18 Aug 03 (Reuters) - Jazz Pharmaceuticals Q2 EPS USD 2.78.
- Q2 net income USD 192.8 million
- Q2 revenue USD 1,208.3 million vs. IBES estimate USD 1,115 million
- Q2 adjusted net income USD 396.4 million vs. IBES estimate USD 410.3 million
- outlook FY revenue USD 4,600-4,750 million vs. IBES estimate USD 4,517 million
Recent news on Jazz Pharmaceuticals
See all newsBrief: Jazz Pharmaceuticals Enters Amendment No. 4 To Credit Agreement On Sept 23, 2026
U.S. STOCKS ON THE MOVE-BWX Technologies, Synopsys,Burlington Stores
U.S. STOCKS ON THE MOVE-Jazz Pharmaceuticals, Celularity, Infleqtion
Jazz Pharma dips after upsized $1.1 bln convertible offering
Brief: Jazz Pharmaceuticals Announces Private Offering Of $1.0 Billion Of Exchangeable Senior Notes Due 2032